U.K. software developer Ultromics has raised 28 million euros, which it plans to use to further develop artificial-intelligence (AI)-supported echocardiograms.
The company was founded in 2017 as a research spin-off from the University of Oxford in England. It has developed two platforms for assessing heart function: EchoGo Core and EchoGo Pro. Both are already being used by U.S. organizations, including the Mayo Clinic in Rochester, MN, and the Oregon Health and Science University in Portland.
The funding round was led by the Blue Venture Fund -- a collaboration of Blue Cross Blue Shield firms, the Blue Cross Blue Shield Association, and Sandbox -- with participation from Optum Ventures and existing investor Oxford Sciences Innovation, the company said.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
